lomustine has been researched along with Cancer, Second Primary in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma." | 4.80 | Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998) |
| "In addition to mechlorethamine, lomustine and teniposide combinations were also linked to an elevated risk of developing leukemia." | 3.69 | Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. ( Chorus, AM; Hagenbeek, A; Noyon, R; Pinedo, HM; Somers, R; van den Belt-Dusebout, AW; van Kerkhoff, EH; van Leeuwen, FE, 1994) |
| "The causes of death were Hodgkin's lymphoma in 36 patients, second neoplasms in 12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6." | 2.72 | MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. ( Broglia, C; Cavanna, L; Chisesi, T; Corazza, GR; Corbella, F; Federico, M; Gobbi, PG; Iannitto, E; La Sala, A; Levis, A; Molica, S; Pavone, V; Sacchi, S; Valentino, F, 2006) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "We describe a case of anaplastic astrocytoma in a 14-year-old boy arising at the site of a dysembryoplastic neuroepithelial tumor (DNT) 3 years after combined radiation and chemotherapy." | 1.32 | Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. ( Mena, H; Rushing, EJ; Thompson, LD, 2003) |
| "Risk of leukemia was 0." | 1.30 | The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con ( Anselmo, AP; Baroni, CD; Bernasconi, C; Brusamolino, E; Klersy, C; Lazzarino, M; Lunghi, F; Mandelli, F; Maurizi-Enrici, R; Orlandi, E; Pagnucco, G; Santoro, M, 1998) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merli, F | 1 |
| Luminari, S | 1 |
| Gobbi, PG | 2 |
| Cascavilla, N | 1 |
| Mammi, C | 1 |
| Ilariucci, F | 1 |
| Stelitano, C | 1 |
| Musso, M | 1 |
| Baldini, L | 1 |
| Galimberti, S | 1 |
| Angrilli, F | 1 |
| Polimeno, G | 1 |
| Scalzulli, PR | 1 |
| Ferrari, A | 1 |
| Marcheselli, L | 1 |
| Federico, M | 2 |
| Nishikawa, R | 1 |
| Packer, RJ | 2 |
| Zhou, T | 1 |
| Holmes, E | 1 |
| Vezina, G | 2 |
| Gajjar, A | 2 |
| Rushing, EJ | 1 |
| Thompson, LD | 1 |
| Mena, H | 1 |
| Broglia, C | 1 |
| Levis, A | 1 |
| La Sala, A | 1 |
| Valentino, F | 1 |
| Chisesi, T | 1 |
| Sacchi, S | 1 |
| Corbella, F | 1 |
| Cavanna, L | 1 |
| Iannitto, E | 1 |
| Pavone, V | 1 |
| Molica, S | 1 |
| Corazza, GR | 1 |
| Rorke-Adams, L | 1 |
| Burger, PC | 1 |
| Robertson, PL | 1 |
| Bayer, L | 1 |
| LaFond, D | 1 |
| Donahue, BR | 1 |
| Marymont, MH | 1 |
| Muraszko, K | 1 |
| Langston, J | 1 |
| Sposto, R | 1 |
| van Leeuwen, FE | 1 |
| Chorus, AM | 1 |
| van den Belt-Dusebout, AW | 1 |
| Hagenbeek, A | 1 |
| Noyon, R | 1 |
| van Kerkhoff, EH | 1 |
| Pinedo, HM | 1 |
| Somers, R | 1 |
| Brusamolino, E | 1 |
| Anselmo, AP | 1 |
| Klersy, C | 1 |
| Santoro, M | 1 |
| Orlandi, E | 1 |
| Pagnucco, G | 1 |
| Lunghi, F | 1 |
| Maurizi-Enrici, R | 1 |
| Baroni, CD | 1 |
| Lazzarino, M | 1 |
| Mandelli, F | 1 |
| Bernasconi, C | 1 |
| Perry, JR | 1 |
| Brown, MT | 1 |
| Gockerman, JP | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Hudson, GV | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 1 |
| Hancock, B | 1 |
| Winfield, D | 1 |
| MacMillan, AK | 1 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Milligan, D | 1 |
| Linch, DC | 1 |
| Molimard, M | 1 |
| Lebeau, B | 1 |
| Longo, DL | 1 |
| DeVita, VT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors[NCT02653196] | Early Phase 1 | 1 participants (Actual) | Interventional | 2015-09-30 | Terminated (stopped due to The Principal Investigator left the institution.) | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA[NCT00002875] | Phase 3 | 421 participants (Actual) | Interventional | 1996-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lomustine and Cancer, Second Primary
| Article | Year |
|---|---|
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome | 1998 |
The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality | 1992 |
5 trials available for lomustine and Cancer, Second Primary
| Article | Year |
|---|---|
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazin | 2016 |
Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemoradiot | 2013 |
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality | 1992 |
5 other studies available for lomustine and Cancer, Second Primary
| Article | Year |
|---|---|
Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell | 2003 |
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Case-Co | 1994 |
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con
Topics: Abdomen; Actuarial Analysis; Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; | 1998 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |
[Occurrence of an epidermoid bronchial carcinoma 8 years after a small cell carcinoma treated with only 3 courses of chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Carcinoma, Bronchogenic; Carcinom | 1992 |